WallStSmart

Merck & Company Inc (MRK)vsOlink Holding AB ADR (OLK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 38385% more annual revenue ($65.77B vs $170.89M). MRK leads profitability with a 13.6% profit margin vs -19.7%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

OLK

Avoid

19

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 4.0Quality: 8.0
Piotroski: 1/9Altman Z: 3.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
OLKSignificantly Overvalued (-44.7%)

Margin of Safety

-44.7%

Fair Value

$18.02

Current Price

$26.08

$8.06 premium

UndervaluedFair: $18.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

OLK2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.2010/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

OLK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-7.0%2/10

ROE of -7.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OLK

The strongest argument for OLK centers on Debt/Equity, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : OLK

The primary concerns for OLK are Revenue Growth, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while OLK is a turnaround play — different risk/reward profiles.

OLK carries more volatility with a beta of 0.52 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Olink Holding AB ADR

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology and other institutions focused on life science research. The company is headquartered in Uppsala, Sweden.

Want to dig deeper into these stocks?